US Medicare confirms reimbursement price for PromarkerD
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd. on 6ix
In the deck
Story so far
Earlier from Proteomics International Laboratories
- Proteomics receives $1.85 million in R&D tax incentive
- September 2023 Quarterly Activities Report and Appendix 4C
- Reinstatement to Quotation
- PromarkerD US reimbursement price & Aus regulatory decision
- Suspension from Quotation
Later from Proteomics International Laboratories
- PromarkerD licence with Omics Global extended to Chile
- December 2023 Quarterly Activities Report and Appendix 4C
- Proteomics to raise $6.5m through Institutional Placement
- Study validates biomarkers for endometriosis blood test
- Study validates biomarkers for oesophageal cancer blood test
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories